By: Ana Elcarte
Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the BOD
07/01/2020Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors CAMBRIDGE, Mass.-- Aura Biosciences, a clinical-stage biopharmaceutical... Read More
Viralgen will open the first drug manufacturing plant of gene therapy in Spain
24/10/2019This infrastructure will involve an investment of more than 50 million euros and will be one of the most advanced in... Read More
Aura Biosciences Announces Clinical Data at AAO 2019 Annual Meeting
02/10/2019Aura Biosciences Announces Clinical Data Presentations at the Upcoming American Academy of Ophthalmology 2019 Annual Meeting CAMBRIDGE, Mass.-- Aura Biosciences,... Read More
Pfizer secures exclusive option to acquire Vivet Therapeutics
20/03/2019Pfizer acquires 15% ownership stake in Vivet Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics (“Vivet”),... Read More
PTS opens the first plant in Europe to manufacture polipeptides
20/03/2019Industrial scale of nanomedicine….
Read MoreColumbus register at the CNMV its second Fund , Columbus Life Science Fund II
04/02/2019Columbus Life Science Fund II will complete the first closing by end of February with a target of €70M MADRID... Read More
Columbus launches its second Fund; €70M for Biomedicine
24/01/2019The venture capital firm has its second fund ready to invest in health sciencie companies Valencia, Spain, January 2019-... Read More
Viralgen Vector Core will be the Gene Therapy reference in Spain
18/09/2018The president of the Basque Government, Iñigo Urkullu, has chaired the inauguration ceremony of Viralgen Vector Core, the first plant of... Read More
Aura Biosciences presents Interim Phase 1b/2 Data at the ASRS Annual Meeting
26/07/2018Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting CAMBRIGE. USA. July... Read More
Aura Biosciences announces Update of Clinical Safety Efficacy
20/06/2018Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma CAMBRIGE. USA. June... Read More